Genomic Valley Biotech Reports Q3FY26 Results with ₹1.05 Lakh Profit; Director Steps Down

Genomic Valley Biotech Limited announced its financial results for the quarter and nine months ended December 31, 2025, alongside significant board changes. The company's Board of Directors convened on January 15, 2026, to approve the unaudited financial results and address directorship matters.

Q3FY26 Financial Performance

The company's third quarter performance showed mixed results compared to previous periods. Key financial metrics for the quarter demonstrate the company's current operational status.

Metric:	Q3FY26	Q3FY25	Change (%)
Revenue from Operations:	₹5.00 lakh	₹22.01 lakh	-77.30%
Total Revenue:	₹5.00 lakh	₹22.05 lakh	-77.30%
Total Expenses:	₹3.95 lakh	₹6.52 lakh	-39.40%
Net Profit:	₹1.05 lakh	₹15.54 lakh	-93.20%
Basic EPS:	₹0.03	₹0.51	-94.10%

The quarterly results indicate a significant decline in revenue from operations, falling from ₹22.01 lakh in Q3FY25 to ₹5.00 lakh in Q3FY26. Despite lower revenues, the company maintained profitability with a net profit of ₹1.05 lakh, though substantially reduced from the previous year's ₹15.54 lakh.

Nine-Month Performance Analysis

The nine-month period ending December 31, 2025, reflects similar trends in the company's financial trajectory.

Parameter:	9M FY26	9M FY25	Variance (%)
Revenue from Operations:	₹23.00 lakh	₹58.04 lakh	-60.40%
Other Income:	Nil	₹0.76 lakh	-100.00%
Total Revenue:	₹23.00 lakh	₹58.81 lakh	-60.90%
Employee Benefits Expense:	₹10.14 lakh	₹7.95 lakh	+27.50%
Net Profit:	₹3.85 lakh	₹43.05 lakh	-91.10%

For the nine-month period, total revenue decreased to ₹23.00 lakh from ₹58.81 lakh in the corresponding previous period. The company recorded a net profit of ₹3.85 lakh compared to ₹43.05 lakh in the same period last year.

Board Changes and Corporate Governance

The Board meeting also addressed significant governance matters, particularly regarding directorship changes.

Details:	Information
Director Name:	Mr. Ashok Kumar
DIN:	07647876
Cessation Date:	January 15, 2026
Reason:	Non-completion of KYC requirements under Section 167 of Companies Act, 2013
Effect:	Immediate cessation from all Board committees

Mr. Ashok Kumar ceased to be a Director and member of all committees of the company with immediate effect from January 15, 2026. The cessation occurred due to non-completion of KYC requirements as mandated under Section 167 of the Companies Act, 2013.

Operational Highlights

The company's operational structure remained consistent with previous periods. Key operational aspects include:

Parameter:	Details
Share Capital:	₹30.55 lakh (equity shares of ₹10 each)
Employee Costs Q3FY26:	₹2.25 lakh
Other Expenses Q3FY26:	₹1.62 lakh
Depreciation Q3FY26:	₹8,000

The financial results were reviewed by the Audit Committee and approved by the Board of Directors. Statutory auditors ANDROS & CO. Chartered Accountants conducted a limited review of the financial results, confirming compliance with applicable Indian Accounting Standards and SEBI regulations. The Board meeting commenced at 5:00 PM and concluded at 5:30 PM on January 15, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.17%	-7.97%	-6.96%	-51.33%	-70.80%	+5.78%

Genomic Valley Biotech Limited (GVBL) has released its unaudited financial results for the first quarter ended June 30, 2025, alongside several key leadership appointments. The company's Board of Directors approved these matters during a meeting held on August 7, 2025.

Financial Performance

GVBL reported a significant decline in both revenue and profit for Q1 FY26 compared to the same period last year:

Particulars (in Rs.)	Q1 FY26	Q1 FY25	% Change
Revenue from Operations	6,16,000.00	9,00,000.00	-31.56
Net Profit	2,46,531.00	12,75,903.00	-80.67

The company's revenue from operations decreased by 31.56% year-over-year, while net profit saw a substantial drop of 80.67%.

Key Appointments

The Board made several important appointments during the meeting:

Secretarial Auditors

M/s. SBR & Co. LLP, Company Secretaries (LLP No. AAO-9057), has been appointed as the Secretarial Auditors for the financial years 2025-2030. The firm, established in 2019, is based in Navi Mumbai with a branch office in Ghaziabad and has over 6 years of experience.

Internal Auditor

Mr. Navjyoti Kumar Jha has been appointed as the Internal Auditor for FY 2025-26. Mr. Jha brings 25 years of experience and holds a Bachelor of Commerce degree.

Chairman & Managing Director

Mr. Yogesh Agrawal has been re-appointed as Chairman & Managing Director for a period of five years, effective September 7, 2025. Mr. Agrawal, aged 62, is a Chartered Accountant with 35 years of business experience. He holds 14,27,000 equity shares in the company and is one of its promoters.

Additional Information

The Board meeting commenced at 3:30 PM and concluded at 4:30 PM on August 7, 2025.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors.
The company's statutory auditors have carried out a limited review of the financial results.

Genomic Valley Biotech continues to operate under the leadership of Mr. Yogesh Agrawal, who has been associated with the company since September 7, 2015. The company's performance in the coming quarters will be closely watched by investors and stakeholders, given the significant decline in revenue and profit during Q1 FY26.